Abbott Laboratories
Company and Pharmaceutical Company
INSIDE WASHINGTON: Stream of WH health care visits...Merck as well as PhRMA, the drug industry's major trade association, and several other of its large members including AstraZeneca and Abbott Labs. Rahm Emanuel had an early July meeting with two labor leaders, John Sweeney, then the... In this article: White House, Barack Obama, Rahm Emanuel, Washington, Ezekiel Emanuel, Blue Cross and Blue Shield Association, Merck & Co., and Nancy-Ann DeParle |
-
MarketWatch | 3 days ago
Peter Brimelow: An extra Thanksgiving for Linde Equity Report
...growth and still rates it as "undervalued," which the HFD also interprets as a buy. In contrast, Linde rated Abbott Laboratories /quotes/comstock/13*!abt/quotes/nls/abt (ABT 54.37, +0.13, +0.24%) , which he bought in March and is up...
In this article: Time horizon and Baidu Inc.
-
Reuters | 6 days ago
Barron's picks 10 stocks as good dividend bets
...AT&T Inc <T.N>. Barron's noted that its next best ten stock picks share many of the virtues of its top picks. These are Abbott Labs <ABT.N>, AT&T, Coca-Cola, Emerson Electric <EMR.N>, Lockheed Martin <LMT.N>, Merck <MRK.N>, Microsoft...
In this article: AT&T Inc, Nestle, Iphone, Banco Santander, Coca-Cola, McDonald's, Revenue, Tylenol, and Verizon Wireless
-
UPDATE 1-US FDA reviewing Abbott diet drug risks
...no conclusions, analysis ongoing U.S. regulators are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc's <ABT.N> weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug...
In this article: Food and Drug Administration, Abbott Laboratories Inc, and U.S.
-
UPDATE 1-FDA warns Abbott over diagnostics manufacturing
...Abbott says already taken steps to address problems (Adds Abbott comment, background) U.S. regulators have warned Abbott Laboratories Inc <ABT.N> about poor manufacturing standards at a molecular diagnostics plant. The U.S. Food and Drug...
In this article: Abbott Laboratories Inc, FDA, Des Plaines, Illinois, and U.S.
-
Seeking Alpha | November 16, 2009
Direction of Cholesterol Debate Could Benefit Abbott Labs
...Vantage November 16, 2009 | about: ABT / AZN / GSK / HGSI / MRK / PFE Arbiter 6-Halts, a study that pitted Abbott Laboratories' (ABT) Niaspan against Merck & Co's (MRK) Zetia, has attracted a lot of attention for such a small trial, the...
In this article: Cholesterol, Niacin, Ezetimibe, Merck, LDL, Statin, Pfizer, Oxford University, and Torcetrapib
-
Fool.com: The Motley Fool | November 13, 2009
Abbott: Brave or Stupid?
Abbott Labs (NYSE: ABT) announced the acquisition of a pain drug, PG110, on Thursday from PanGenetics that has me wondering how painful this acquisition will be on the company's ego. Compare the structure of this deal with other recent...
In this article: Abbott Labs and NYSE
-
chicagotribune.com - Business | November 12, 2009
Abbott buying experimental pain drug
2:13 p.m. CST, November 12, 2009 Bolstering its stable of drugs derived from human cells, Abbott Laboratories said Thursday that it will acquire the worldwide rights to an experimental pain drug from Dutch biotech firm PanGenetics BV for...
In this article: Chronic pain and Chicago
-
The Seattle Times | November 12, 2009
Abbott buys pain drug candidate for up to $190M
...published Thursday, November 12, 2009 at 7:10 AM Abbott buys pain drug candidate for up to $190M Abbott Laboratories said Thursday it is buying a potential chronic pain drug from PanGenetics BV for as much as $190 million. Abbott...
In this article: Chronic pain, Cancer, Arthritis, and Netherlands
-
Xconomy | November 10, 2009
Alder Rides Momentum of $1B Deal, Aims to Give Amgen and Abbott a Run for Their Money
...approach could offer doctors an alternative to the $10 billion-a-year class of biotech drugs, like Amgen's etanercept (Enbrel) and Abbott Laboratories' adalimumab (Humira). When asked directly whether Alder's clinical trial shows it is...
In this article: Amgen, Rheumatoid arthritis, Adalimumab, Bristol-Myers Squibb, Seattle, and Orencia
Trends
Loading...
More on Abbott Laboratories
Description from Wikipedia:
Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals health care company. It has 72,000 employees and operates in over 130 countries. The corporate headquarters are in Abbott Park, Illinois, located near North Chicago, Illinois.
Abbott Laboratories was founded by Chicago physician Wallace Calvin Abbott in 1888. In 2008, Abbott had over $29 billion in revenue.
In 1985, the company developed the first HIV blood screening test. The company's drug portfolio includes Humira, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis; Norvir, a treatment for HIV; Depakote, an anticonvulsant drug; and Synthroid, a synthetic thyroid hormone. Abbott also has a broad range of medical devices, diagnostics and immunoassay products as well as nutritional products, including Ensure, a line of well known meal replacement shakes, and EAS, the largest producer of performance based nutritional supplements.
Abbott’s in vitro diagnostics business is a world leader in immunoassays and blood screening. Abbott’s broad range of medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other important indicators of general health.
Abbott Point-of-Care manufactures diagnostic products for blood analysis to provide health care professionals critical diagnostics information accurately and immediately at the point of patient care. In addition to its offerings in the blood gas and chemistries segment, Abbott also provides point-of-care cardiac assays to the emergency room.
- Name:
- Abbott Laboratories
- Type:
- Public (NYSE: ABT)
- Location:
- Abbott Park, IL, USA
- Region:
- Worldwide
- Founder:
- Dr. Wallace C. Abbott
- Founded:
- 1888 (as Abbott Alkaloidal Company)
- Stock Symbol:
- ABT
- Key People:
- Miles D. White
- Products:
-
- Animal health products
- Diagnostic assays
- Pharmaceutical products
- Medical devices
- Nutritional products
- Revenue:
- US$ 29.528 billion (2008)
- Operating Income:
- US$ 5.694 billion (2008)
- Net Income:
- US$ 4.881 billion (2008)
- Assets:
- US$ 39.713 billion (2007)
- Equity:
- US$ 17.778 billion (2007)
- No. of Employees:
- 72,000 (2009)
- Motto:
- A promise for life
- Market Cap:
- US$ 81.94 billion (2009)
Explore everything named Abbott Laboratories...
